These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

809 related items for PubMed ID: 27866027

  • 1. Cardiovascular outcomes with sodium-glucose cotransporter-2 inhibitors in patients with type II diabetes mellitus: A meta-analysis of placebo-controlled randomized trials.
    Saad M, Mahmoud AN, Elgendy IY, Abuzaid A, Barakat AF, Elgendy AY, Al-Ani M, Mentias A, Nairooz R, Bavry AA, Mukherjee D.
    Int J Cardiol; 2017 Feb 01; 228():352-358. PubMed ID: 27866027
    [Abstract] [Full Text] [Related]

  • 2. Meta-Analysis of Effects of Sodium-Glucose Cotransporter 2 Inhibitors on Cardiovascular Outcomes and All-Cause Mortality Among Patients With Type 2 Diabetes Mellitus.
    Tang H, Fang Z, Wang T, Cui W, Zhai S, Song Y.
    Am J Cardiol; 2016 Dec 01; 118(11):1774-1780. PubMed ID: 27666177
    [Abstract] [Full Text] [Related]

  • 3. Effects of SGLT-2 inhibitors on mortality and cardiovascular events: a comprehensive meta-analysis of randomized controlled trials.
    Monami M, Dicembrini I, Mannucci E.
    Acta Diabetol; 2017 Jan 01; 54(1):19-36. PubMed ID: 27488726
    [Abstract] [Full Text] [Related]

  • 4. Sodium-glucose co-transporter 2 inhibitors and cardiovascular outcomes: A systematic review and meta-analysis.
    Usman MS, Siddiqi TJ, Memon MM, Khan MS, Rawasia WF, Talha Ayub M, Sreenivasan J, Golzar Y.
    Eur J Prev Cardiol; 2018 Mar 01; 25(5):495-502. PubMed ID: 29372664
    [Abstract] [Full Text] [Related]

  • 5. Effects of sodium-glucose cotransporter-2 inhibitors on cardiovascular events, death, and major safety outcomes in adults with type 2 diabetes: a systematic review and meta-analysis.
    Wu JH, Foote C, Blomster J, Toyama T, Perkovic V, Sundström J, Neal B.
    Lancet Diabetes Endocrinol; 2016 May 01; 4(5):411-9. PubMed ID: 27009625
    [Abstract] [Full Text] [Related]

  • 6. Sodium Glucose Cotransporter 2 Inhibitors in the Treatment of Diabetes Mellitus: Cardiovascular and Kidney Effects, Potential Mechanisms, and Clinical Applications.
    Heerspink HJ, Perkins BA, Fitchett DH, Husain M, Cherney DZ.
    Circulation; 2016 Sep 06; 134(10):752-72. PubMed ID: 27470878
    [Abstract] [Full Text] [Related]

  • 7. Effects of Dipeptidyl Peptidase 4 Inhibitors and Sodium-Glucose Linked coTransporter-2 Inhibitors on cardiovascular events in patients with type 2 diabetes mellitus: A meta-analysis.
    Savarese G, D'Amore C, Federici M, De Martino F, Dellegrottaglie S, Marciano C, Ferrazzano F, Losco T, Lund LH, Trimarco B, Rosano GM, Perrone-Filardi P.
    Int J Cardiol; 2016 Oct 01; 220():595-601. PubMed ID: 27390996
    [Abstract] [Full Text] [Related]

  • 8. Cardiovascular Events Associated With SGLT-2 Inhibitors Versus Other Glucose-Lowering Drugs: The CVD-REAL 2 Study.
    Kosiborod M, Lam CSP, Kohsaka S, Kim DJ, Karasik A, Shaw J, Tangri N, Goh SY, Thuresson M, Chen H, Surmont F, Hammar N, Fenici P, CVD-REAL Investigators and Study Group.
    J Am Coll Cardiol; 2018 Jun 12; 71(23):2628-2639. PubMed ID: 29540325
    [Abstract] [Full Text] [Related]

  • 9. Network meta-analysis of cardiovascular outcomes in randomized controlled trials of new antidiabetic drugs.
    Fei Y, Tsoi MF, Kumana CR, Cheung TT, Cheung BMY.
    Int J Cardiol; 2018 Mar 01; 254():291-296. PubMed ID: 29277321
    [Abstract] [Full Text] [Related]

  • 10. Effects of sodium-glucose cotransporter type 2 inhibitors on cardiovascular, renal, and safety outcomes in patients with cardiovascular disease: a meta-analysis of randomized controlled trials.
    Zheng C, Lin M, Chen Y, Xu H, Yan L, Dai H.
    Cardiovasc Diabetol; 2021 Apr 22; 20(1):83. PubMed ID: 33888126
    [Abstract] [Full Text] [Related]

  • 11. Cardiovascular Safety of Dipeptidyl-Peptidase IV Inhibitors: A Meta-Analysis of Placebo-Controlled Randomized Trials.
    Elgendy IY, Mahmoud AN, Barakat AF, Elgendy AY, Saad M, Abuzaid A, Wayangankar SA, Bavry AA.
    Am J Cardiovasc Drugs; 2017 Apr 22; 17(2):143-155. PubMed ID: 27873238
    [Abstract] [Full Text] [Related]

  • 12. The role of sodium glucose cotransporter-2 (SGLT-2) inhibitors in heart failure and chronic kidney disease in type 2 diabetes.
    Woo V, Connelly K, Lin P, McFarlane P.
    Curr Med Res Opin; 2019 Jul 22; 35(7):1283-1295. PubMed ID: 30767677
    [Abstract] [Full Text] [Related]

  • 13. Cardiovascular Safety, Long-Term Noncardiovascular Safety, and Efficacy of Sodium-Glucose Cotransporter 2 Inhibitors in Patients With Type 2 Diabetes Mellitus: A Systemic Review and Meta-Analysis With Trial Sequential Analysis.
    Zhang XL, Zhu QQ, Chen YH, Li XL, Chen F, Huang JA, Xu B.
    J Am Heart Assoc; 2018 Jan 20; 7(2):. PubMed ID: 29353233
    [Abstract] [Full Text] [Related]

  • 14. [Outcome studies on SGLT-2 inhibitors].
    Seufert J, Laubner K.
    Internist (Berl); 2019 Sep 20; 60(9):903-911. PubMed ID: 31375850
    [Abstract] [Full Text] [Related]

  • 15. Cardiovascular Outcomes in Patients Initiating First-Line Treatment of Type 2 Diabetes With Sodium-Glucose Cotransporter-2 Inhibitors Versus Metformin : A Cohort Study.
    Shin H, Schneeweiss S, Glynn RJ, Patorno E.
    Ann Intern Med; 2022 Jul 20; 175(7):927-937. PubMed ID: 35605236
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Effects of sodium-glucose cotransporter (SGLT) inhibitors in addition to insulin therapy on glucose control and safety outcomes in adults with type 1 diabetes: A meta-analysis of randomized controlled trials.
    Lu J, Tang L, Meng H, Zhao J, Liang Y.
    Diabetes Metab Res Rev; 2019 Oct 20; 35(7):e3169. PubMed ID: 30974510
    [Abstract] [Full Text] [Related]

  • 18. Effect of SGLT-2 inhibitors on cardiovascular outcomes in heart failure patients: A meta-analysis of randomized controlled trials.
    Lu Y, Li F, Fan Y, Yang Y, Chen M, Xi J.
    Eur J Intern Med; 2021 May 20; 87():20-28. PubMed ID: 33824055
    [Abstract] [Full Text] [Related]

  • 19. Effects of the Sodium-Glucose Cotransporter Inhibitors on Cardiovascular Death and All-Cause Mortality: A Systematic Review and Meta-analysis of Randomized Placebo-Controlled Clinical Trials.
    Eraikhuemen N, Leung S, Warren SB, Lazaridis D, Smith CH, Kearson ML, Marcellus V.
    Am J Cardiovasc Drugs; 2023 Mar 20; 23(2):113-126. PubMed ID: 36572841
    [Abstract] [Full Text] [Related]

  • 20. Lower Risk of Death With SGLT2 Inhibitors in Observational Studies: Real or Bias?
    Suissa S.
    Diabetes Care; 2018 Jan 20; 41(1):6-10. PubMed ID: 29263192
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 41.